首页 > 最新文献

Indian Journal of Pharmacology最新文献

英文 中文
Acute generalized exanthematous pustulosis following ceftriaxone. 服用头孢曲松后出现急性全身泛发性脓疱病。
IF 2.4 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-10 DOI: 10.4103/ijp.ijp_127_24
Mauli M Shah,Shree Dhanani,Keyur Patel,Pragya Nair
{"title":"Acute generalized exanthematous pustulosis following ceftriaxone.","authors":"Mauli M Shah,Shree Dhanani,Keyur Patel,Pragya Nair","doi":"10.4103/ijp.ijp_127_24","DOIUrl":"https://doi.org/10.4103/ijp.ijp_127_24","url":null,"abstract":"","PeriodicalId":13490,"journal":{"name":"Indian Journal of Pharmacology","volume":"12 1","pages":"297-298"},"PeriodicalIF":2.4,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142206516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correlation between essential metals and severe acute respiratory syndrome coronavirus 2 infection. 必需金属与严重急性呼吸系统综合征冠状病毒 2 感染之间的相关性。
IF 2.4 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-10 DOI: 10.4103/ijp.ijp_735_23
Anoop Kumar,Manisha Thakur,Mohini Chaurasia,S J S Flora
{"title":"Correlation between essential metals and severe acute respiratory syndrome coronavirus 2 infection.","authors":"Anoop Kumar,Manisha Thakur,Mohini Chaurasia,S J S Flora","doi":"10.4103/ijp.ijp_735_23","DOIUrl":"https://doi.org/10.4103/ijp.ijp_735_23","url":null,"abstract":"","PeriodicalId":13490,"journal":{"name":"Indian Journal of Pharmacology","volume":"21 1","pages":"299-300"},"PeriodicalIF":2.4,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142226424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Implementing pharmacogenetic testing to optimize proton-pump inhibitors use among Indian population based on CPIC-CYP2C19-PPI dosing guidelines: The need of the hour. 根据 CPIC-CYP2C19-PPI 剂量指南,在印度人群中实施药物基因检测,以优化质子泵抑制剂的使用:当务之急。
IF 2.4 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-10 DOI: 10.4103/ijp.ijp_198_24
Santenna Chenchula,Shubham Atal,Ratinder Jhaj,Chakradhara Rao S Uppugunduri
Proton-pump inhibitors (PPIs) are widely prescribed to decrease stomach acid and treat various acid-related Gastrointestinal tract (GIT) diseases. However, genetic variations, particularly in the CYP2C19 gene, affect PPIs metabolism and efficacy. Variants in CYP2C19 can result in different rates of PPI metabolism, influencing their effectiveness. Personalized medicine strategies, such as genotyping for CYP2C19, have the potential to enhance the effectiveness of PPI therapy and patient safety. This review aims to describe the relevance of CYP2C19 genetic profiling in the indian population, including normal function (e.g. CYP2C19*1, *11, *13, *15, *18, *28, and 38), decreased function (e.g., CYP2C19*9, *10, *16, *19, *25, and 26), loss of function (e.g., CYP2C19*2, *3, *4, *5, *6, *7, *8, *22, *24, *35, *36, and *37), and increased function (e.g., CYP2C19*17) variants. This review also examines the clinical pharmacogenomics implementation consortium (CPIC)-CYP2C19-PPI guidelines to highlight the importance of pharmacogenomics (PGx)-informed personalized PPI therapy for gastroesophageal reflux disease and peptic ulcer disease treatment. On average, each person in India possesses eight pharmacogenetic (PGx) variants that can be clinically significant, underscoring the need for preemptive testing. Implementing CYP2C19 genetic testing in India requires expanding laboratory capacity, increasing accessibility in primary care, increasing public awareness, collaboration between pharmacovigilance and PGx programs, investing in advanced sequencing technologies, data management systems, and integration with electronic health records and clinical decision support systems. Addressing challenges such as genetic diversity, socioeconomic factors, health-care access issues, and shortage of trained professionals is essential for implementation. Due to the lack of definitive country-specific policies and PGx guidelines from Indian drug regulatory agencies, guidelines from international consortia such as the Clinical Pharmacogenetics Implementation Consortium and drug labeling offer crucial foundational evidence. This evidence can be used to enhance patient outcomes and ensure the safe and effective use of PPIs in India.
质子泵抑制剂(PPIs)被广泛用于减少胃酸和治疗各种与胃酸有关的胃肠道(GIT)疾病。然而,基因变异,尤其是 CYP2C19 基因的变异,会影响 PPIs 的代谢和疗效。CYP2C19 基因变异会导致 PPI 代谢率不同,从而影响其疗效。个性化医疗策略(如 CYP2C19 基因分型)有可能提高 PPI 治疗的有效性和患者的安全性。本综述旨在描述 CYP2C19 基因图谱分析在印度人群中的相关性,包括正常功能(如 CYP2C19*1、*11、*13、*15、*18、*28 和 38)、功能减退(如 CYP2C19*9、*13、*15、*18、*28 和 38)、CYP2C19*9、*10、*16、*19、*25 和 26)、功能丧失(如 CYP2C19*2、*3、*4、*5、*6、*7、*8、*22、*24、*35、*36 和 *37)以及功能增强(如 CYP2C19*17)变体。本综述还研究了临床药理基因组学实施联盟(CPIC)-CYP2C19-PPI 指南,以强调以药物基因组学(PGx)为依据的个性化 PPI 治疗对胃食管反流病和消化性溃疡病治疗的重要性。在印度,平均每个人都有八个药物基因组学(PGx)变异,这些变异可能具有重要的临床意义,这就强调了预先检测的必要性。在印度实施 CYP2C19 基因检测需要扩大实验室能力、提高初级保健的可及性、提高公众意识、药物警戒与 PGx 项目之间的合作、投资于先进的测序技术、数据管理系统以及与电子健康记录和临床决策支持系统的整合。应对基因多样性、社会经济因素、医疗保健普及问题和训练有素的专业人员短缺等挑战对于项目的实施至关重要。由于印度药品监管机构缺乏针对具体国家的明确政策和 PGx 指南,临床药物遗传学实施联盟等国际联盟的指南和药品标签提供了重要的基础证据。这些证据可用于提高患者的治疗效果,确保在印度安全有效地使用 PPIs。
{"title":"Implementing pharmacogenetic testing to optimize proton-pump inhibitors use among Indian population based on CPIC-CYP2C19-PPI dosing guidelines: The need of the hour.","authors":"Santenna Chenchula,Shubham Atal,Ratinder Jhaj,Chakradhara Rao S Uppugunduri","doi":"10.4103/ijp.ijp_198_24","DOIUrl":"https://doi.org/10.4103/ijp.ijp_198_24","url":null,"abstract":"Proton-pump inhibitors (PPIs) are widely prescribed to decrease stomach acid and treat various acid-related Gastrointestinal tract (GIT) diseases. However, genetic variations, particularly in the CYP2C19 gene, affect PPIs metabolism and efficacy. Variants in CYP2C19 can result in different rates of PPI metabolism, influencing their effectiveness. Personalized medicine strategies, such as genotyping for CYP2C19, have the potential to enhance the effectiveness of PPI therapy and patient safety. This review aims to describe the relevance of CYP2C19 genetic profiling in the indian population, including normal function (e.g. CYP2C19*1, *11, *13, *15, *18, *28, and 38), decreased function (e.g., CYP2C19*9, *10, *16, *19, *25, and 26), loss of function (e.g., CYP2C19*2, *3, *4, *5, *6, *7, *8, *22, *24, *35, *36, and *37), and increased function (e.g., CYP2C19*17) variants. This review also examines the clinical pharmacogenomics implementation consortium (CPIC)-CYP2C19-PPI guidelines to highlight the importance of pharmacogenomics (PGx)-informed personalized PPI therapy for gastroesophageal reflux disease and peptic ulcer disease treatment. On average, each person in India possesses eight pharmacogenetic (PGx) variants that can be clinically significant, underscoring the need for preemptive testing. Implementing CYP2C19 genetic testing in India requires expanding laboratory capacity, increasing accessibility in primary care, increasing public awareness, collaboration between pharmacovigilance and PGx programs, investing in advanced sequencing technologies, data management systems, and integration with electronic health records and clinical decision support systems. Addressing challenges such as genetic diversity, socioeconomic factors, health-care access issues, and shortage of trained professionals is essential for implementation. Due to the lack of definitive country-specific policies and PGx guidelines from Indian drug regulatory agencies, guidelines from international consortia such as the Clinical Pharmacogenetics Implementation Consortium and drug labeling offer crucial foundational evidence. This evidence can be used to enhance patient outcomes and ensure the safe and effective use of PPIs in India.","PeriodicalId":13490,"journal":{"name":"Indian Journal of Pharmacology","volume":"30 1","pages":"277-284"},"PeriodicalIF":2.4,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142226423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Applying quantitative and systems pharmacology to drug development and beyond: An introduction to clinical pharmacologists 将定量和系统药理学应用于药物开发及其他领域:临床药理学家入门
IF 2.4 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-10 DOI: 10.4103/ijp.ijp_644_23
Mathan Kumar Ramasubbu, Bhairav Paleja, Anand Srinivasann, Rituparna Maiti, Rukmini Kumar

Quantitative and systems pharmacology (QSP) is an innovative and integrative approach combining physiology and pharmacology to accelerate medical research. This review focuses on QSP’s pivotal role in drug development and its broader applications, introducing clinical pharmacologists/researchers to QSP’s quantitative approach and the potential to enhance their practice and decision-making. The history of QSP adoption reveals its impact in diverse areas, including glucose regulation, oncology, autoimmune disease, and HIV treatment. By considering receptor–ligand interactions of various cell types, metabolic pathways, signaling networks, and disease biomarkers simultaneously, QSP provides a holistic understanding of interactions between the human body, diseases, and drugs. Integrating knowledge across multiple time and space scales enhances versatility, enabling insights into personalized responses and general trends. QSP consolidates vast data into robust mathematical models, predicting clinical trial outcomes and optimizing dosing based on preclinical data. QSP operates under a “learn and confirm paradigm,” integrating experimental findings to generate testable hypotheses and refine them through precise experimental designs. An interdisciplinary collaboration involving expertise in pharmacology, biochemistry, genetics, mathematics, and medicine is vital. QSP’s utility in drug development is demonstrated through integration in various stages, predicting drug responses, optimizing dosing, and evaluating combination therapies. Challenges exist in model complexity, communication, and peer review. Standardized workflows and evaluation methods ensure reliability and transparency.

定量与系统药理学(QSP)是一种创新的综合方法,它将生理学与药理学相结合,以加速医学研究。本综述重点介绍 QSP 在药物开发中的关键作用及其更广泛的应用,向临床药理学家/研究人员介绍 QSP 的定量方法及其增强实践和决策的潜力。QSP 的应用历史揭示了它在不同领域的影响,包括葡萄糖调节、肿瘤学、自身免疫疾病和 HIV 治疗。通过同时考虑各种细胞类型的受体-配体相互作用、代谢途径、信号网络和疾病生物标志物,QSP 提供了对人体、疾病和药物之间相互作用的整体理解。跨时间和空间尺度的知识整合增强了通用性,使人们能够深入了解个性化反应和总体趋势。QSP 将大量数据整合到强大的数学模型中,根据临床前数据预测临床试验结果并优化剂量。QSP 在 "学习和确认范式 "下运行,通过整合实验结果来生成可检验的假设,并通过精确的实验设计来完善这些假设。涉及药理学、生物化学、遗传学、数学和医学专业知识的跨学科合作至关重要。QSP 在药物开发、药物反应预测、剂量优化和联合疗法评估等不同阶段的整合应用,证明了 QSP 的实用性。在模型复杂性、交流和同行评审方面存在挑战。标准化的工作流程和评估方法可确保可靠性和透明度。
{"title":"Applying quantitative and systems pharmacology to drug development and beyond: An introduction to clinical pharmacologists","authors":"Mathan Kumar Ramasubbu, Bhairav Paleja, Anand Srinivasann, Rituparna Maiti, Rukmini Kumar","doi":"10.4103/ijp.ijp_644_23","DOIUrl":"https://doi.org/10.4103/ijp.ijp_644_23","url":null,"abstract":"<p>Quantitative and systems pharmacology (QSP) is an innovative and integrative approach combining physiology and pharmacology to accelerate medical research. This review focuses on QSP’s pivotal role in drug development and its broader applications, introducing clinical pharmacologists/researchers to QSP’s quantitative approach and the potential to enhance their practice and decision-making. The history of QSP adoption reveals its impact in diverse areas, including glucose regulation, oncology, autoimmune disease, and HIV treatment. By considering receptor–ligand interactions of various cell types, metabolic pathways, signaling networks, and disease biomarkers simultaneously, QSP provides a holistic understanding of interactions between the human body, diseases, and drugs. Integrating knowledge across multiple time and space scales enhances versatility, enabling insights into personalized responses and general trends. QSP consolidates vast data into robust mathematical models, predicting clinical trial outcomes and optimizing dosing based on preclinical data. QSP operates under a “learn and confirm paradigm,” integrating experimental findings to generate testable hypotheses and refine them through precise experimental designs. An interdisciplinary collaboration involving expertise in pharmacology, biochemistry, genetics, mathematics, and medicine is vital. QSP’s utility in drug development is demonstrated through integration in various stages, predicting drug responses, optimizing dosing, and evaluating combination therapies. Challenges exist in model complexity, communication, and peer review. Standardized workflows and evaluation methods ensure reliability and transparency.</p>","PeriodicalId":13490,"journal":{"name":"Indian Journal of Pharmacology","volume":"65 1","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142206513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacomicrobiomics - Another frontier of precision medicine. 药物微生物组学--精准医疗的另一个前沿领域。
IF 2.4 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-10 DOI: 10.4103/ijp.ijp_646_24
Santenna Chenchula,Shubham Atal,Anusuya Bhattacharyya,Bikash Medhi,Madhavrao Chavan,Phulen Sarma
{"title":"Pharmacomicrobiomics - Another frontier of precision medicine.","authors":"Santenna Chenchula,Shubham Atal,Anusuya Bhattacharyya,Bikash Medhi,Madhavrao Chavan,Phulen Sarma","doi":"10.4103/ijp.ijp_646_24","DOIUrl":"https://doi.org/10.4103/ijp.ijp_646_24","url":null,"abstract":"","PeriodicalId":13490,"journal":{"name":"Indian Journal of Pharmacology","volume":"24 1","pages":"237-241"},"PeriodicalIF":2.4,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142206517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advancing pediatric drug development in South Asia: Current landscape and vision for the future 推动南亚儿科药物开发:当前形势与未来愿景
IF 2.4 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-10 DOI: 10.4103/ijp.ijp_396_24
Rajesh Krishna, Manoj Jadhav, Rama Sivasubramanian, Gangadhar Sunkara, Vikram Gota, Vis Niranjan, Vipin Dhote, Nidhi Sapkal, Nirmala N Rege, Samir Sethi, Bikash Medhi, Nilima Kshirsagar, Deven Parmar

The manuscript summarizes the outcomes of a one-day conference by the South Asian College of American College of Clinical Pharmacology (SAC-ACCP) in July 2023, at Bhopal. The theme of the conference was “Advancing pediatric drug development in South Asia.” SAC-ACCP organized this event in Bhopal to foster the discipline of clinical pharmacology and to motivate researchers and physicians in the in the central part of India. The conference featured presentations on regional approaches to pediatric drug development in Asia by pediatric scientific experts from the pharmaceutical industry, regulatory agencies, as well as independent consultancies. The speakers highlighted several important aspects of the evolving regulatory landscape in India and proposed numerous actionable steps in acceleration of pediatric drug development. This commentary provides insights from presentations and the panel discussion at this conference and also makes an attempt to connect to similar discussions that occurred at the SAC-ACCP drug development conference in 2017.

该手稿总结了美国临床药理学院南亚学院(SAC-ACCP)于 2023 年 7 月在博帕尔举行的为期一天的会议的成果。会议的主题是 "推进南亚儿科药物开发"。SAC-ACCP 在博帕尔举办此次活动的目的是促进临床药理学学科的发展,激励印度中部地区的研究人员和医生。来自制药行业、监管机构和独立咨询机构的儿科科学专家在会上就亚洲儿科药物开发的区域方法作了发言。发言者强调了印度不断变化的监管环境的几个重要方面,并提出了许多加快儿科药物开发的可行步骤。本评论从本次会议的演讲和小组讨论中提出了见解,并试图与 2017 年 SAC-ACCP 药物开发会议上的类似讨论相联系。
{"title":"Advancing pediatric drug development in South Asia: Current landscape and vision for the future","authors":"Rajesh Krishna, Manoj Jadhav, Rama Sivasubramanian, Gangadhar Sunkara, Vikram Gota, Vis Niranjan, Vipin Dhote, Nidhi Sapkal, Nirmala N Rege, Samir Sethi, Bikash Medhi, Nilima Kshirsagar, Deven Parmar","doi":"10.4103/ijp.ijp_396_24","DOIUrl":"https://doi.org/10.4103/ijp.ijp_396_24","url":null,"abstract":"<p>The manuscript summarizes the outcomes of a one-day conference by the South Asian College of American College of Clinical Pharmacology (SAC-ACCP) in July 2023, at Bhopal. The theme of the conference was “Advancing pediatric drug development in South Asia.” SAC-ACCP organized this event in Bhopal to foster the discipline of clinical pharmacology and to motivate researchers and physicians in the in the central part of India. The conference featured presentations on regional approaches to pediatric drug development in Asia by pediatric scientific experts from the pharmaceutical industry, regulatory agencies, as well as independent consultancies. The speakers highlighted several important aspects of the evolving regulatory landscape in India and proposed numerous actionable steps in acceleration of pediatric drug development. This commentary provides insights from presentations and the panel discussion at this conference and also makes an attempt to connect to similar discussions that occurred at the SAC-ACCP drug development conference in 2017.</p>","PeriodicalId":13490,"journal":{"name":"Indian Journal of Pharmacology","volume":"9 1","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142206515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anecdotal and experimental observation of putative onco-regressive factors in urine: The need for detailed further investigation. 从轶事和实验中观察到尿液中存在假定的副回归因子:需要进一步详细调查。
IF 2.4 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-10 DOI: 10.4103/ijp.ijp_270_24
Ashok D B Vaidya
{"title":"Anecdotal and experimental observation of putative onco-regressive factors in urine: The need for detailed further investigation.","authors":"Ashok D B Vaidya","doi":"10.4103/ijp.ijp_270_24","DOIUrl":"https://doi.org/10.4103/ijp.ijp_270_24","url":null,"abstract":"","PeriodicalId":13490,"journal":{"name":"Indian Journal of Pharmacology","volume":"5 1","pages":"295-296"},"PeriodicalIF":2.4,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142226422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A novel ultra-performance liquid chromatography detection method development and validation for paclitaxel and its major metabolite in human plasma. 针对人血浆中紫杉醇及其主要代谢物的新型超高效液相色谱检测方法的开发与验证。
IF 2.4 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-10 DOI: 10.4103/ijp.ijp_557_23
Vikas Kumar,Gyan Vardhan,Amit Sehrawat,Shailendra Handu,Puneet Dhamija
BACKGROUNDPaclitaxel is a promising anticancer drug for patients with ovarian, breast, lung, gastrointestinal, genitourinary, prostate, and head-and-neck cancers. Paclitaxel follows nonlinear pharmacokinetics. The major metabolite of paclitaxel is 6-alpha-hydroxy paclitaxel, mediated by CYP2C8, while metabolism to two of its minor metabolites, 3'-p-hydroxypaclitaxel and 6a, 3'- p-dihydroxypaclitaxel, is catalyzed by CYP3A4. Therapeutic drug monitoring of paclitaxel could be a promising approach to improve the efficacy and safety of paclitaxel correct personalized doses and improve the overall benefit-risk ratio. A novel and highly sensitive chromatographic method for the detection of paclitaxel and its metabolite has been proposed that allows quantification in human plasma with 100% accuracy in terms of recovery without significant intraday or interday variations.MATERIALS AND METHODSThe present study was planned following bioanalytical method validation guidance according to the U.S. Food and Drug Administration requirements. The validation of the analytical procedure was performed as per ICH Q2(R1) guidelines. It was done to assure the reliability of the results obtained for various parameters such as linearity, accuracy, precision, limit of detection (LOD), limit of quantification, robustness, stability, and system suitability.RESULTSThe specificity of the method was established by ensuring no interference with peak obtained from paclitaxel and 6-alpha-hydroxy paclitaxel. LOD was found to be 0.05 and 0.033 while the limit of quantitation was 0.14 and 0.099 for paclitaxel and 6-alpha-hydroxy paclitaxel, respectively. Median (±interquartile range) accuracy for paclitaxel and 6-alpha-hydroxy paclitaxel was found to be 102.73 (±13.581) and 100.87 (±7.573), respectively.CONCLUSIONThis novel method of simultaneous detection of paclitaxel and its major metabolite 6-alpha-hydroxy paclitaxel demonstrated significant resolution and was sensitive enough for its quantification in human plasma.
背景紫杉醇是一种对卵巢癌、乳腺癌、肺癌、胃肠道癌、泌尿生殖系统癌、前列腺癌和头颈癌患者很有希望的抗癌药物。紫杉醇的药代动力学呈非线性。紫杉醇的主要代谢产物是 6-α- 羟基紫杉醇,由 CYP2C8 介导,而其两种次要代谢产物 3'-p- 羟基紫杉醇和 6a、3'- p- 二羟基紫杉醇则由 CYP3A4 催化代谢。对紫杉醇进行治疗药物监测是提高紫杉醇正确的个性化剂量的疗效和安全性、改善总体收益风险比的一种可行方法。本研究提出了一种新型高灵敏度色谱法来检测紫杉醇及其代谢物,该方法可对人体血浆中的紫杉醇及其代谢物进行定量检测,回收率准确率达 100%,且日内或日间无明显变化。分析程序的验证根据 ICH Q2(R1) 指南进行。结果通过确保紫杉醇和 6-α- 羟基紫杉醇的峰值不受干扰,确定了该方法的特异性。紫杉醇和 6-α- 羟基紫杉醇的检出限分别为 0.05 和 0.033,定量限分别为 0.14 和 0.099。紫杉醇和 6-α- 羟基紫杉醇的准确度中位数(±四分位间范围)分别为 102.73 (±13.581) 和 100.87 (±7.573)。
{"title":"A novel ultra-performance liquid chromatography detection method development and validation for paclitaxel and its major metabolite in human plasma.","authors":"Vikas Kumar,Gyan Vardhan,Amit Sehrawat,Shailendra Handu,Puneet Dhamija","doi":"10.4103/ijp.ijp_557_23","DOIUrl":"https://doi.org/10.4103/ijp.ijp_557_23","url":null,"abstract":"BACKGROUNDPaclitaxel is a promising anticancer drug for patients with ovarian, breast, lung, gastrointestinal, genitourinary, prostate, and head-and-neck cancers. Paclitaxel follows nonlinear pharmacokinetics. The major metabolite of paclitaxel is 6-alpha-hydroxy paclitaxel, mediated by CYP2C8, while metabolism to two of its minor metabolites, 3'-p-hydroxypaclitaxel and 6a, 3'- p-dihydroxypaclitaxel, is catalyzed by CYP3A4. Therapeutic drug monitoring of paclitaxel could be a promising approach to improve the efficacy and safety of paclitaxel correct personalized doses and improve the overall benefit-risk ratio. A novel and highly sensitive chromatographic method for the detection of paclitaxel and its metabolite has been proposed that allows quantification in human plasma with 100% accuracy in terms of recovery without significant intraday or interday variations.MATERIALS AND METHODSThe present study was planned following bioanalytical method validation guidance according to the U.S. Food and Drug Administration requirements. The validation of the analytical procedure was performed as per ICH Q2(R1) guidelines. It was done to assure the reliability of the results obtained for various parameters such as linearity, accuracy, precision, limit of detection (LOD), limit of quantification, robustness, stability, and system suitability.RESULTSThe specificity of the method was established by ensuring no interference with peak obtained from paclitaxel and 6-alpha-hydroxy paclitaxel. LOD was found to be 0.05 and 0.033 while the limit of quantitation was 0.14 and 0.099 for paclitaxel and 6-alpha-hydroxy paclitaxel, respectively. Median (±interquartile range) accuracy for paclitaxel and 6-alpha-hydroxy paclitaxel was found to be 102.73 (±13.581) and 100.87 (±7.573), respectively.CONCLUSIONThis novel method of simultaneous detection of paclitaxel and its major metabolite 6-alpha-hydroxy paclitaxel demonstrated significant resolution and was sensitive enough for its quantification in human plasma.","PeriodicalId":13490,"journal":{"name":"Indian Journal of Pharmacology","volume":"4 1","pages":"253-259"},"PeriodicalIF":2.4,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142206519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Can baxdrostat revamp resistant hypertension status in India? baxdrostat 能改变印度的耐药性高血压状况吗?
IF 2.4 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-10 DOI: 10.4103/ijp.ijp_141_24
Elisha Paikray,Satyajit Mohapatra
{"title":"Can baxdrostat revamp resistant hypertension status in India?","authors":"Elisha Paikray,Satyajit Mohapatra","doi":"10.4103/ijp.ijp_141_24","DOIUrl":"https://doi.org/10.4103/ijp.ijp_141_24","url":null,"abstract":"","PeriodicalId":13490,"journal":{"name":"Indian Journal of Pharmacology","volume":"25 1","pages":"293-294"},"PeriodicalIF":2.4,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142226425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prospective, randomized, placebo-controlled, two-arm study to evaluate the efficacy of coadministration of garlic as a hydrogen sulfide donor and tadalafil in patients with erectile dysfunction not responding to tadalafil alone – A pilot study 一项前瞻性、随机、安慰剂对照、双臂研究,旨在评估大蒜作为硫化氢供体与他达拉非联合应用对单用他达拉非无效的勃起功能障碍患者的疗效--一项试点研究
IF 2.4 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-10 DOI: 10.4103/ijp.ijp_310_23
Gajanan Shripad Bhat, Anuradha Shastry

OBJECTIVE: 

The objective is to evaluate the efficacy of coadministration of garlic (as a hydrogen sulfide [H2S] donor) and tadalafil for patients with ED using a placebo-controlled, prospective, randomized, two-arm pilot study in patients responding poorly to tadalafil alone.

MATERIALS AND METHODS: 

The patients with complaints of ED (with normal penile Doppler) who failed to maintain sustained improvement in erectile function with tadalafil were recruited after excluding those with comorbidities. The study sample was randomized into two groups. Group A received garlic 5 g twice a day orally and Group B received a placebo twice daily orally for 4 weeks. Both groups continued tadalafil 5 mg in the night for 4 weeks. Their erectile function was assessed at the beginning and at the end of 4 weeks using the International Index of Erectile Function (IIEF-EF), erectile function domain and compared. A value of P ≤ 0.05 was considered statistically significant.

RESULTS: 

Nineteen patients in Group A (mean age 37.5 ± 10.6 years) and 16 patients in Group B (mean age 39.6 ± 9.6 years) participated in the pilot study conducted from May 2022 to August 2022. The participants treated with garlic (as an H2S donor) as a coadministrant had statistically significant improvement in IIEF-EF score (P ≤ 0.0001) at the end of 4 weeks compared to placebo.

CONCLUSIONS: 

Garlic (as an H2S donor) as adjunctive therapy was beneficial in our study participants responding poorly to tadalafil alone.

材料与方法:在排除合并症患者后,招募主诉ED(阴茎多普勒正常)且服用他达拉非后勃起功能未能持续改善的患者。研究样本被随机分为两组。A 组每天口服两次大蒜,每次 5 克;B 组每天口服两次安慰剂,每次 4 周。两组均在夜间服用 5 毫克他达拉非,持续 4 周。在4周开始和结束时,使用国际勃起功能指数(IIEF-EF)和勃起功能域对他们的勃起功能进行评估和比较。结果:A组19名患者(平均年龄(37.5 ± 10.6)岁)和B组16名患者(平均年龄(39.6 ± 9.6)岁)参加了2022年5月至2022年8月进行的试点研究。与安慰剂相比,接受大蒜(作为 H2S 供体)辅助治疗的参与者在 4 周结束时 IIEF-EF 评分有显著改善(P ≤ 0.0001):结论:大蒜(作为 H2S 供体)作为辅助疗法对我们的研究对象有益,因为他们对单独服用他达拉非的反应不佳。
{"title":"Prospective, randomized, placebo-controlled, two-arm study to evaluate the efficacy of coadministration of garlic as a hydrogen sulfide donor and tadalafil in patients with erectile dysfunction not responding to tadalafil alone – A pilot study","authors":"Gajanan Shripad Bhat, Anuradha Shastry","doi":"10.4103/ijp.ijp_310_23","DOIUrl":"https://doi.org/10.4103/ijp.ijp_310_23","url":null,"abstract":"<h3>OBJECTIVE: </h3>\u0000<p>The objective is to evaluate the efficacy of coadministration of garlic (as a hydrogen sulfide [H<sub xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">2</sub>S] donor) and tadalafil for patients with ED using a placebo-controlled, prospective, randomized, two-arm pilot study in patients responding poorly to tadalafil alone.</p>\u0000<h3>MATERIALS AND METHODS: </h3>\u0000<p>The patients with complaints of ED (with normal penile Doppler) who failed to maintain sustained improvement in erectile function with tadalafil were recruited after excluding those with comorbidities. The study sample was randomized into two groups. Group A received garlic 5 g twice a day orally and Group B received a placebo twice daily orally for 4 weeks. Both groups continued tadalafil 5 mg in the night for 4 weeks. Their erectile function was assessed at the beginning and at the end of 4 weeks using the International Index of Erectile Function (IIEF-EF), erectile function domain and compared. A value of <em xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">P</em> ≤ 0.05 was considered statistically significant.</p>\u0000<h3>RESULTS: </h3>\u0000<p>Nineteen patients in Group A (mean age 37.5 ± 10.6 years) and 16 patients in Group B (mean age 39.6 ± 9.6 years) participated in the pilot study conducted from May 2022 to August 2022. The participants treated with garlic (as an H<sub xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">2</sub>S donor) as a coadministrant had statistically significant improvement in IIEF-EF score (<em xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">P</em> ≤ 0.0001) at the end of 4 weeks compared to placebo.</p>\u0000<h3>CONCLUSIONS: </h3>\u0000<p>Garlic (as an H<sub xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">2</sub>S donor) as adjunctive therapy was beneficial in our study participants responding poorly to tadalafil alone.</p>","PeriodicalId":13490,"journal":{"name":"Indian Journal of Pharmacology","volume":"40 1","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142206514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Indian Journal of Pharmacology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1